PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib
2024

How HMGA1 Affects Esophageal Cancer Sensitivity to Olaparib

publication 10 minutes Evidence: high

Author Information

Author(s): Lei Xin‐Yuan, He Kai‐Yue, Li Qiu‐Tong, Zhang Lei, Wu Dan‐Hui, Yang Jing‐Yu, Guo Jin‐Rong, Liu Meng‐Jie, Zhao Zi‐Long, Li Jun‐Qi, Liu Huai, Zhao Yuan, Li Yu‐Jia, Sun Qian‐Hui, Wu Chen‐Guang, Wang Yun‐Fan, Cao Geng‐Sheng, Wang Gang, Jian Yong‐Ping, Xu Zhi‐Xiang

Primary Institution: School of Life Sciences, Henan University, Kaifeng, China

Hypothesis

Does the PARylation of HMGA1 influence the sensitivity of esophageal squamous cell carcinoma to olaparib?

Conclusion

Targeting HMGA1 could enhance the sensitivity of esophageal cancer cells to the drug olaparib.

Supporting Evidence

  • HMGA1 is highly expressed in esophageal squamous cell carcinoma tissues.
  • Depletion of HMGA1 increases tumor sensitivity to olaparib.
  • HMGA1 interacts with PARP1 and is modified by PARylation during DNA damage.
  • Targeting HMGA1 could be a promising strategy to enhance cancer treatment efficacy.

Takeaway

HMGA1 is a protein that helps cancer cells survive damage from treatments. If we block it, the cancer cells become more sensitive to a drug called olaparib.

Methodology

The study involved experiments on esophageal cancer cells to assess the role of HMGA1 in DNA damage repair and sensitivity to olaparib.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/ctm2.70111

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication